Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced the appointment of Colin Hayward, MBBS, FFPM, as the company’s Chief Medical Officer. Dr. Hayward brings more than 26 years of global experience in the healthcare industry, including leadership in oncology, haemato-oncology, and rare diseases, with the last six years focused on radiopharmaceuticals and translational medicine.
“Colin joins Ratio at an important time as we advance our radiopharmaceutical pipeline and further progress the ATLAS trial, a Phase 1/2 study of [Ac-225]-RTX-2358 in patients with relapsed or refractory soft tissue sarcomas,” said Dr. Jack Hoppin, Chairman and Chief Executive Officer of Ratio. “His extensive experience in clinical development and medical affairs will be invaluable in guiding the trial’s design, execution, and oversight, ensuring we generate robust data while maintaining the highest standards of patient care.”
“I am honored to join Ratio during such a dynamic period for the radiopharmaceutical industry,” said Dr. Colin Hayward, Chief Medical Officer of Ratio. “I look forward to working with the talented team to advance the ATLAS trial and our broader clinical programs. Ratio has the technology to make a meaningful impact for patients, and I am excited to help translate our targeted radiopharmaceuticals into effective therapies for those who need them most.”
Prior to joining Ratio, Dr. Hayward served as Chief Medical Officer at Telix Pharmaceuticals, where he led the Medical Affairs and Clinical Development teams, overseeing oncology, hematology, and rare disease programs, including first-in-human studies and regulatory interactions with FDA and global agencies. Previously, he held leadership roles at Premier Research, Myriad Genetics, and Roche, managing international medical affairs, clinical development, and strategic drug development initiatives across multiple therapeutic areas.
Dr. Hayward earned his MBBS in Medicine from University of London, Guy’s and St Thomas’s Hospitals, and is a Fellow of the Faculty of Pharmaceutical Medicine (FFPM).
Also read: Viksit Workforce for a Viksit Bharat
Do Follow: The Mainstream LinkedIn | The Mainstream Facebook | The Mainstream Youtube | The Mainstream Twitter
About us:
The Mainstream is a premier platform delivering the latest updates and informed perspectives across the technology business and cyber landscape. Built on research-driven, thought leadership and original intellectual property, The Mainstream also curates summits & conferences that convene decision makers to explore how technology reshapes industries and leadership. With a growing presence in India and globally across the Middle East, Africa, ASEAN, the USA, the UK and Australia, The Mainstream carries a vision to bring the latest happenings and insights to 8.2 billion people and to place technology at the centre of conversation for leaders navigating the future.
